Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating expenses
Research and development	$ (361,484)	$ (640,425)
Selling, general and administrative	(2,753,482)	(2,935,863)
Total operating expenses	(3,114,966)	(3,576,288)
Loss from operations	(3,114,966)	(3,576,288)
Other expenses:
Impairment loss	(500,000)	(1,834,672)
Interest expense	(82,594)	(94,576)
Total other expenses	(582,594)	(1,929,248)
Net loss	(3,697,560)	(5,505,536)
Deemed dividend on preferred stock	627,705
Net loss applicable to common stockholders	$ (4,325,265)	$ (5,505,536)
Net loss per share—basic and diluted	$ (0.34)	$ (0.50)
Weighted average number of common shares outstanding – basic and diluted	12,859,938	11,121,871